<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

Newsroom

Press Releases

Our latest announcements

Biodesix Receives CE Mark for VeriStrat Specimen Collection and Shipping Kit

CE Mark clears Biodesix to make VeriStrat results available to physicians in the European Union and other countries recognizing the CE Mark.

Biodesix and Capital Royalty Close Financing Transaction

Biodesix has closed a structured debt financing with Capital Royalty Partners L.P. The transaction provides Biodesix®with up to $20 million of capital.

Biodesix Adds to Series E Financing

Biodesix increases the size of its recent offering of series E preferred shares in a follow-on sale; Total series E preferred shares of $14.4 million.

Biodesix Closes Series E Financing

Biodesix announced today that the company closed an $8.3 million Series E preferred equity financing. Existing shareholders provided all of the capital.

Biodesix to Present at World CDx

Paul Beresford, Ph.D., will present at the 2013 World CDx Summit taking place in Boston, November 12-15, 2013; Benefits of proteomics in test discovery.

Biodesix® Announces Additional Data in Phase III Lung Cancer Diagnostic Study

PROSE confirms VeriStrat can predict differential treatment outcomes in 2nd line advanced NCLSC patients.

Biodesix Secures Medicare Coverage for VeriStrat Test

Bioesix's Veristrat test gains coverage from Medicare. More than 49 million Medicare enrollees in the U.S. will now be able to benefit from VeriStrat.

Biodesix Announces Results in Phase III Lung Cancer Diagnostic Study; First Prospective Biomarker-Stratified Validation Study in Oncology

Data confirms that the blood-based protein diagnostic is predictive of differential treatment outcomes between two types of therapies for 2nd line NSCLC.

Biodesix to Announce Results of VeriStrat® Biomarker Study

Biodesix presents data on VeriStrat biomarker study at ASCO 2013

Biodesix Closes Series D Financing

Biodesix closed on $8.8 million in a follow-on sale of its Series D preferred shares.